Ketoconazole Shortage: What Providers and Prescribers Need to Know in 2026

While ketoconazole does not appear on the FDA's national drug shortage list in 2026, prescribers across specialties are encountering patients who report difficulty filling ketoconazole prescriptions — particularly for specialty topical formulations and oral tablets at smaller pharmacies. This guide provides a clinical overview of the current availability landscape, prescribing considerations given the drug's significant safety restrictions, and therapeutic substitution strategies.

Current Availability Status (2026)

Generic ketoconazole 200 mg tablets and 2% topical cream are available from multiple manufacturers and generally in adequate supply at major retail chains. However, branded specialty topical products — including Extina (ketoconazole 2% foam) and Xolegel/Ketodan (ketoconazole 2% gel) — have experienced intermittent distribution gaps at individual pharmacies and in specific geographic markets.

Oral ketoconazole 200 mg tablets are less commonly stocked than topical forms, reflecting the dramatically reduced prescription volume following FDA's 2013 safety communications restricting its use to last-resort systemic fungal infections. Some community pharmacies in rural areas may not keep oral ketoconazole in inventory and require 1–3 days to order.

FDA Regulatory Context: What Every Prescriber Should Know

Oral ketoconazole carries a black box warning with three critical restrictions:

Hepatotoxicity: Serious hepatotoxicity, including cases with a fatal outcome or requiring liver transplantation, has occurred with oral ketoconazole. Obtain liver function tests (ALT, AST, bilirubin) at baseline and monitor throughout treatment. If ALT rises above the upper limit of normal or more than 30% above baseline, interrupt dosing and reassess.

QT Prolongation: Ketoconazole inhibits CYP3A4 and can elevate plasma concentrations of co-administered drugs that prolong the QT interval. Contraindicated with dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, and ranolazine.

Last-resort use only: Oral ketoconazole should be used only when alternative antifungal therapy is not available or not tolerated, and only for endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, paracoccidioidomycosis). It should not be prescribed as first-line treatment for skin or nail fungal infections, oral candidiasis, or vaginal candidiasis.

Note: Topical ketoconazole formulations (cream, shampoo, foam, gel) are not subject to these systemic safety restrictions, as skin absorption is minimal. They remain first- or second-line options for seborrheic dermatitis, tinea versicolor, and superficial candidiasis.

Drug Interaction Profile: A High-Risk Medicine for Complex Patients

Oral ketoconazole is a potent inhibitor of CYP3A4 and P-glycoprotein, generating an extensive drug interaction profile. RxList data indicates ketoconazole has severe interactions with at least 33 drugs, serious interactions with more than 200 drugs, and moderate interactions with over 240 drugs. Key interaction categories to review before prescribing:

Contraindicated combinations: QT-prolonging agents (listed above), simvastatin/lovastatin (rhabdomyolysis risk), triazolam/oral midazolam/alprazolam (extreme sedation), ergot derivatives (vasospasm)

Requires dose adjustment: Tacrolimus, cyclosporine, warfarin, many oncology agents (cabazitaxel, dasatinib, erlotinib, ibrutinib), amlodipine and other CCBs

Absorption interactions: Antacids, H2 blockers, and PPIs reduce ketoconazole absorption; if co-administration is necessary, administer with an acidic beverage such as non-diet cola and space from antacids

Therapeutic Substitution Guidance

When a patient cannot access ketoconazole, the appropriate substitution depends on the indication:

Seborrheic dermatitis (scalp/face): Ciclopirox 1% shampoo or cream; selenium sulfide 2.5%; zinc pyrithione OTC shampoo

Tinea versicolor: Selenium sulfide 2.5% lotion; single-dose fluconazole 400 mg PO (off-label); itraconazole 200 mg/day x 5–7 days

Cutaneous dermatophytosis: Terbinafine cream/gel (OTC) or oral terbinafine for extensive or resistant infections; clotrimazole (OTC)

Systemic endemic mycoses: Itraconazole (preferred for histoplasmosis, blastomycosis); fluconazole (preferred for coccidioidomycosis); voriconazole or amphotericin B for severe/refractory cases. Consult ID specialist.

Cushing's syndrome (off-label): Metyrapone or osilodrostat if ketoconazole unavailable; consult endocrinology

Supporting Patients Who Can't Fill Ketoconazole Prescriptions

Providers can point patients to medfinder for providers — a service that calls pharmacies near the patient to find which ones can fill the prescription. This is particularly helpful for patients prescribed less-common formulations (foam, gel) or those in areas with limited pharmacy options.

Practical clinical tips:

Write "Brand or generic acceptable" on prescriptions for topical ketoconazole to maximize filling options

Pre-authorize refills at 2–3 months at a time to reduce re-ordering burden for patients on chronic topical ketoconazole

Consider prescribing compounded ketoconazole topical preparations when commercial formulations are consistently unavailable — many compounding pharmacies can prepare 2% ketoconazole cream at reasonable cost

For oral ketoconazole patients with systemic infections, ensure patients have a clear 2–3 day emergency supply and a plan if their pharmacy runs low

Monitoring Requirements for Oral Ketoconazole

If oral ketoconazole is clinically necessary despite the safety restrictions:

Obtain baseline liver function tests (ALT, AST, ALP, bilirubin) before starting

Monitor liver function weekly for the first month, then monthly

Educate patients to report symptoms of liver dysfunction: fatigue, abdominal pain, jaundice, dark urine

Conduct a thorough medication reconciliation before prescribing, given the extensive CYP3A4 interaction profile

Document in the medical record that alternative antifungal therapies were considered and found unavailable or not tolerated — this is required for appropriate prescribing under the FDA's guidance

Summary for Clinical Practice

Ketoconazole's complicated safety profile means prescribers should default to safer alternatives whenever possible. When it must be used — especially in the oral form — careful patient selection, thorough drug interaction screening, and close liver function monitoring are essential. For patients who do need ketoconazole and are having trouble finding it at pharmacies, directing them to medfinder can help bridge the access gap quickly.